About this research
In order to participate in this study, you must be able to speak and read Dutch fluently.
The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is a capsule that is taken orally.
In the brains of people with Alzheimer’s disease, certain proteins stick together. This eventually leads to changes in thinking and behaviour. It is hoped that PRI‑002 can cut these proteins back into small pieces. That could reduce the effects of Alzheimer’s disease.
You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 10 to 13 times, during approximately 1 to 2 years. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 1 hour, others 3.5 hours. The research takes place in Amsterdam, Den Bosch or Zwolle.
This study is commissioned by PRInnovation GmbH.
How does the application process go?
You always decide whether you participate in a study. Participation is always voluntary.
- You apply via the online form, this is non-binding.
- After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
- You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
- When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
- If you decide to participate in the study, you sign a form and will start the study within several weeks.
What are the benefits of Brain Research Center?
- You always come first – everything we do revolves around you.
- Experienced team of doctors, neuropsychologists, and nurses.
- Open and homely atmosphere – this will make you feel relaxed and right at home.
- Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
- Always nearby – 3 locations spread through the Netherlands.
What's in it for me?
- You may experience benefits from a new treatment.
- You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
- You make a meaningful contribution to a future without Alzheimer’s.
- You contribute to the advancement of science.
Can I participate?
You can participate when:
- You have MCI or a mild form of dementia caused by Alzheimer’s disease
- You are between 55 and 80 years old
- You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.
Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate.
Latest Alzheimer’s trials
Efavirenz
The goal of this study is to evaluate how safe and effective the drug efavirenz is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the drug efavirenz with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’).
55 - 75 years
Early stage of Alzheimer's
Approximately 18 weeks
Amsterdam
Polaris AD
The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.
55 - 90 years
Early Alzheimer’s disease (MCI or mild AD
1 to 2 years
Amsterdam, Den Bosch or Zwolle
PRImus AD
The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.
55 - 80 years
MCI or a mild form of dementia caused by Alzheimer’s disease
Approximately 1 to 2 years
Amsterdam, Den Bosch or Zwolle